Global major in patient-focused innovation for structural heart disease and critical care monitoring, Edwards Lifesciences Corporation EW is making.

May 17, 2023 04:25 AM Eastern Daylight Time. NEWBURY, England--(BUSINESS WIRE) ... Current technologies utilizing this novel tissue include the INSPIRIS RESILIA aortic valve, ...

MISSISSAUGA, Ontario, Jan. 25, 2018 /CNW/ -- Edwards Lifesciences Corporation, the global leader in patient-focused innovations for structural hea ...

The company’s most recent breakthrough, the Inspiris Resilia aortic valve, is constructed on the Perimount platform and features Resilia tissue and VFit technology. Inspiris stands as the ...

Lighting Rock Research Fri, Oct. 25, 2024. Edwards Lifesciences: ... It also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; ...

“Given that TAVR is mounted on a flexible stent, unlike Inspiris with Resilia tissue mounted on a rigid surgical valve frame, we will need to determine the long-term outcomes of Resilia in a ...

CAIRO, April 18, 2025--Edwards Lifesciences (NYSE: EW) today announced new eight-year data showing that patients receiving aortic surgical valves treated with its proprietary RESILIA tissue ...

EDWARDS' AORTIC VALVE WITH RESILIA TISSUE SHOWS FAVORABLE DURABILITY, SAFETY AND EFFICACY OUTCOMES IN SEVEN YEAR DATA . NEWBURY, May 16 th, 2023 -- Edwards Lifesciences announced new data from the ...